CRP and non-small cell lung carcinoma: In non-small cell lung cancer (NSCLC), early CRP reduction after immune checkpoint inhibitor (ICI) initiation correlates significantly with improved OS and PFS, suggesting utility as a pharmacodynamic biomarker (12, 13).